Provides guidelines for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism, addressing the impact of inherited risk factors on anticoagulation strategies.
Standardizes anticoagulation duration decisions in VTE with thrombophilia; extends prior guidelines via updated evidence synthesis.
Venous thromboembolism (VTE) is a term that includes both deep venous thrombosis (DVT) and pulmonary embolism (PE). Considerable progress has been made in the understanding of the risk factors for VTE. The clinical applications of molecular techniques have facilitated identification of important inherited, yet not uncommon risk factors for VTE. Factor V Leiden (1–5) and prothrombin G20210A mutation (6–10) are among the most common. Such progress raised many questions regarding the need for and duration of anticoagulation.
No takes yet. Share an insight, caveat, or question.
Abdel‐Razeq et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: